entertainment -WSS

entertainment

author：leisure time 2025-10-01 17:34:12 - browse：33665

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront.

The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million. Carmot is privately held, though it had filed paperwork last month for an initial public offering.

As part of the deal, Roche is gaining three experimental obesity medicines from Carmot, which are in Phase 1 or Phase 2 testing, as well as preclinical programs. While two are injectable treatments, one is being developed as an oral drug. They all target GLP-1 hormone receptors, while two are also designed to work via receptors for another hormone called GIP.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA investigates CAR

focus

Wikipedia

WSS

As biotech industry slumps, bioscience job market is upside down

ReNAgade cuts staff seven months after raising $300 million

U.K. Biobank has 500,000 peoples' genome sequences available

Diagnostic tests are hitting their mathematical limits

In 'major milestone,' FDA approves first cell therapy for solid tumors

New study raises questions about niacin and heart health

focus

entertainment

focus

After affirmative action ruling, medical educators look to 'holistic review'

Diagnostic tests are hitting their mathematical limits

At least 13 dead in Texas as scorching temps continue

Hospitals are piloting generative AI tools as regulators play catch

Hollywood unions extend contract negotiations for actors

Weight loss drugs aren’t covered by Obamacare. That may change

United colonoscopy coverage change 'may cost lives,' doctors say

What don’t we know about an Alzheimer’s drug side effect?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pediatric cancer treatments threatened by a new FDA policy

entertainment

Secretariat’s lessons for human medicine

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

MD Anderson's Padmanee Sharma responds to research credit suit

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

New study raises questions about niacin and heart health

entertainment

focus

Wikipedia

entertainment